Merck & Co. stock gains on Wells Fargo price target hike and cancer vaccine momentum
Published on 09/07/2026 at 15:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (ISIN US58933Y1055) stock is trading around USD 150 in early September 2026, close to its recent closing level of USD 150.34 as of September 6, 2026, while investors digest fresh analyst upgrades and ongoing progress in the company’s personalized cancer vaccine program.
Analyst upgrade and trial news support Merck & Co. stock
A key catalyst for Merck & Co. stock on September 7, 2026 is a price target increase from Wells Fargo & Co, which raised its target from USD 150 to USD 170 while maintaining an overweight rating, signaling renewed confidence in the company’s valuation upside based on its pipeline and earnings outlook as of that date.
At the same time, Merck & Co. is in the spotlight due to positive trial results for the personalized cancer vaccine intismeran autogene, developed in partnership with Moderna, which revived investor interest in the oncology franchise according to a recap from TradingView news dated September 7, 2026.
Earnings and guidance frame the valuation
For investors, the current valuation of Merck & Co. stock rests on its most recently reported quarterly figures and full-year guidance for fiscal 2026, which show a combination of moderate revenue growth and a still-supportive margin and return profile relative to peers.
Merck & Co., Inc. last posted quarterly earnings on August 4, 2026 for its latest quarter, reporting earnings per share of negative USD 0.13, which nevertheless beat the consensus estimate of negative USD 0.26 by USD 0.13 according to data compiled by MarketBeat.
In the same release for that quarter ended in 2026, Merck & Co. reported revenue of USD 16.61 billion versus analyst expectations of USD 16.37 billion, meaning sales came in USD 0.24 billion above consensus and representing a 5.1 percent increase compared with the same quarter of the prior year when revenue had been lower.
That prior-year period had earnings per share of USD 2.13, so the swing to negative EPS this quarter reflects specific one-off effects, but the company still posted a net margin of 4.77 percent and a return on equity of 16.73 percent in the latest reported quarter, underlining that its underlying profitability and capital efficiency remain solid on a trailing basis.
Merck & Co. has also set its fiscal year 2026 guidance at an earnings per share range of USD 2.66 to USD 2.76, and equities research analysts currently forecast full-year EPS of USD 2.76, framing expectations for the year relative to the current share price, as summarized by MarketBeat.
Dividend profile and analyst consensus
Alongside earnings, Merck & Co. stock is supported by a regular dividend profile, which remains an important part of the total return story for income-oriented investors looking at large-cap healthcare names.
The company has declared a quarterly dividend of USD 0.85 per share, representing an annualized payout of USD 3.40 and implying a dividend yield of about 2.3 percent at recent price levels near USD 150 per share, according to recent institutional holding reports compiled by MarketBeat.
At the time of those reports, the payout ratio associated with the dividend was stated at 272.00 percent, a figure that reflects the impact of one-off items on current-period earnings and suggests investors should focus on normalized earnings and cash flow rather than the latest quarter alone when assessing dividend sustainability.
From an analyst perspective, data gathered by MarketBeat show that Merck & Co. currently carries a consensus rating described as moderate buy, with an average price target of around USD 148.60 across the coverage universe, while other overviews such as Pluang note a consensus target in the area of USD 155, indicating a clustered view of modest upside from the current price zone.
Stock level, market capitalization and technical context
As of September 7, 2026, Merck & Co. stock is quoted at about USD 150.34 on its primary listing on the New York Stock Exchange, with the latest snapshot indicating the shares are down roughly 1.31 percent on the day but still supported by bullish technical signals from moving averages, according to comparative data compiled by Pluang.
That same comparative overview lists Merck & Co. with a market capitalization of USD 370.89 billion as of September 7, 2026, positioning the company firmly among the largest global healthcare and pharmaceutical players and underscoring the scale investors are paying for when they consider the stock.
The recent price around USD 150 sits near the consensus analyst target of USD 148.60 reported by MarketBeat and below the newly raised USD 170 target from Wells Fargo, meaning the upgrade implies upside of roughly 13 percent from the latest trading level if the higher target is achieved.
In addition, some performance comparisons show Merck & Co. stock has gained about 75.3 percent over the last twelve months, according to an alternative-data screen from Altindex, a move that explains why valuation multiples such as the price-to-earnings ratio stand at elevated levels around 120.3 based on current reported earnings.
Risks and counter-factors around the cancer vaccine story
While the positive intismeran autogene trial news and Wells Fargo’s price target increase provide a supportive narrative, investors in Merck & Co. stock also need to weigh the usual clinical, regulatory and competitive risks linked to oncology and vaccine development.
The TradingView recap on September 7, 2026 notes that Merck’s 13 percent stake in Personalis and its support for Tempus AI’s USD 1.5 billion sale at USD 16.25 per share tie strategic sequencing partnerships directly to the cancer vaccine program, meaning execution risk in these alliances could influence the ultimate commercial value of intismeran autogene and related products.
In addition, the current high price-to-earnings ratio and the temporary distortion of earnings from one-off items imply that any disappointment in future quarters relative to the EPS guidance range of USD 2.66 to USD 2.76 for 2026 could lead to a reassessment of the stock’s valuation, especially if margin metrics such as the 4.77 percent net margin were to weaken.
From a more traditional risk angle, the 272.00 percent payout ratio derived from the latest quarter’s earnings underlines how accounting volatility can make dividend metrics look stretched in the short term, so Merck & Co. will need to demonstrate that underlying cash generation continues to support the USD 3.40 annual dividend over time.
Keytruda and oncology franchise as a long-term driver
For many shareholders, the long-term appeal of Merck & Co. stock is tied to its broad oncology portfolio, with flagship products such as the immuno-oncology therapy Keytruda acting as major revenue contributors alongside newer pipeline assets like the personalized cancer vaccine intismeran autogene.
While the latest quarterly report summarized by MarketBeat focuses on aggregate revenue of USD 16.61 billion and year-on-year growth of 5.1 percent, the underlying composition of that sales figure includes a significant share from oncology products, meaning trial success and regulatory approvals in this area will be crucial to maintaining or accelerating the top-line trajectory.
Against that backdrop, the strategic stakes in data and sequencing specialists such as Personalis and the backing of Tempus AI’s USD 1.5 billion sale suggest Merck & Co. is positioning itself to integrate advanced diagnostics and data analytics into its oncology development, a move that could deepen its competitive moat if executed successfully.
Merck & Co. stock and investor takeaways
For investors assessing Merck & Co. stock in early September 2026, a few concrete numbers frame the current situation: a share price of about USD 150.34 as of September 7, 2026, a market capitalization near USD 370.89 billion, quarterly revenue of USD 16.61 billion up 5.1 percent year-on-year, EPS guidance of USD 2.66 to USD 2.76 for fiscal 2026, and a USD 3.40 annual dividend implying roughly a 2.3 percent yield.
Set against the newly raised USD 170 price target from Wells Fargo and the consensus targets clustered around the high USD 140s to mid USD 150s, these figures indicate that the market already prices in a substantial share of Merck & Co.’s oncology potential, but still leaves room for upside if current cancer vaccine trials and strategic partnerships deliver on expectations.
Oncology product focus: Keytruda and personalized cancer vaccines
Among Merck & Co.’s broad product range, the oncology franchise anchored by Keytruda remains the most visible for many investors, given its established role in treating multiple tumor types and its contribution to group revenue over recent years.
In parallel, the intismeran autogene personalized cancer vaccine program, developed with Moderna and supported by sequencing and data partnerships, illustrates how Merck & Co. is pushing into next-generation oncology approaches that rely on tailoring immune responses to individual tumor signatures.
Stock price context and closing view
Merck & Co. stock is trading at around USD 150.34 on the New York Stock Exchange as of September 7, 2026, modestly below the fresh USD 170 price target from Wells Fargo but close to the broader analyst consensus range, leaving investors watching upcoming earnings releases and oncology trial updates to judge whether the shares can close that gap.
Merck & Co. stock key data
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Trading venue: NYSE
- Price (as of September 7, 2026): 150.34 USD
- Market capitalization: 370.89 billion USD (as of September 7, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: S&P 500
